Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Replimune Group, Inc. (NASDAQ:REPL) have been given a consensus rating of “Buy” by the six research firms that are presently covering the company, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $16.80.

Several brokerages recently commented on REPL. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Roth Mkm initiated coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Replimune Group in a research note on Monday, September 16th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th.

Insider Transactions at Replimune Group

In other news, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction on Friday, August 16th. The shares were sold at an average price of $10.18, for a total transaction of $90,988.84. Following the transaction, the chief financial officer now owns 101,057 shares in the company, valued at $1,028,760.26. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 8.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of REPL. Price T Rowe Associates Inc. MD grew its stake in Replimune Group by 12.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock valued at $53,505,000 after buying an additional 699,679 shares during the last quarter. Millennium Management LLC grew its stake in Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after buying an additional 2,656,173 shares during the last quarter. Vanguard Group Inc. grew its stake in Replimune Group by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock valued at $22,634,000 after buying an additional 32,555 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Replimune Group by 300.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company’s stock valued at $18,874,000 after buying an additional 1,679,553 shares during the last quarter. Finally, Clearbridge Investments LLC grew its stake in Replimune Group by 2.7% in the 1st quarter. Clearbridge Investments LLC now owns 277,969 shares of the company’s stock valued at $2,271,000 after buying an additional 7,274 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Stock Down 0.4 %

Shares of NASDAQ:REPL opened at $11.96 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 13.46 and a current ratio of 13.46. The company has a market cap of $817.11 million, a PE ratio of -3.66 and a beta of 1.21. Replimune Group has a 52 week low of $4.92 and a 52 week high of $15.18. The firm has a 50 day simple moving average of $10.93 and a 200 day simple moving average of $8.97.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.10. As a group, research analysts expect that Replimune Group will post -3.05 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.